ZA967732B - Pharmaceutical combination preparations containing erythropoietin and ferric complexes. - Google Patents
Pharmaceutical combination preparations containing erythropoietin and ferric complexes.Info
- Publication number
- ZA967732B ZA967732B ZA9607732A ZA967732A ZA967732B ZA 967732 B ZA967732 B ZA 967732B ZA 9607732 A ZA9607732 A ZA 9607732A ZA 967732 A ZA967732 A ZA 967732A ZA 967732 B ZA967732 B ZA 967732B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical combination
- preparations containing
- combination preparations
- containing erythropoietin
- ferric complexes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention is directed to a pharmaceutical combination preparation comprising 2,000-7,000 U of recombinant human erythropoietin (EPO) and 5-20 mg of an Fe(III) complex, wherein the rhEPO and the Fe(III) complex may be present in separate administration forms or in an integrated administration form.The pharmaceutical preparation is used in the treatment of anemias or hemodialysis patients.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19535571A DE19535571A1 (en) | 1995-09-14 | 1995-09-14 | Combined pharmaceutical preparations and their use for the treatment of hemodialysis patients |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA967732B true ZA967732B (en) | 1998-03-13 |
Family
ID=7773098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9607732A ZA967732B (en) | 1995-09-14 | 1996-09-13 | Pharmaceutical combination preparations containing erythropoietin and ferric complexes. |
Country Status (26)
Country | Link |
---|---|
US (2) | US6333306B1 (en) |
EP (1) | EP0851762B1 (en) |
JP (1) | JP4783482B2 (en) |
KR (1) | KR100350761B1 (en) |
CN (1) | CN1133463C (en) |
AT (1) | ATE216256T1 (en) |
AU (1) | AU724623B2 (en) |
BR (1) | BR9609971A (en) |
CA (1) | CA2231192C (en) |
CZ (1) | CZ291427B6 (en) |
DE (3) | DE19535571A1 (en) |
DK (1) | DK0851762T3 (en) |
EE (1) | EE03856B1 (en) |
ES (1) | ES2174107T3 (en) |
HU (1) | HU225363B1 (en) |
IL (2) | IL123640A0 (en) |
MX (1) | MX9801922A (en) |
NO (1) | NO329908B1 (en) |
NZ (1) | NZ319132A (en) |
PL (1) | PL186776B1 (en) |
PT (1) | PT851762E (en) |
SK (1) | SK285796B6 (en) |
TR (1) | TR199800472T1 (en) |
UA (1) | UA57713C2 (en) |
WO (1) | WO1997009996A1 (en) |
ZA (1) | ZA967732B (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI0977582T1 (en) * | 1997-03-18 | 2002-12-31 | Roche Diagnostics Gmbh | Pharmaceutical combined preparations containing erythropoietin and iron preparations |
EP0885613A1 (en) * | 1997-06-21 | 1998-12-23 | Roche Diagnostics GmbH | Use of modified hemoglobins for treatment of anemias and erythropoietin and modified hemoglobin containing combined preparations |
DE19734293A1 (en) | 1997-08-08 | 1999-02-11 | Boehringer Mannheim Gmbh | Use of pharmaceutical combination preparations containing erythropoietin and iron preparations for the treatment of rheumatic diseases |
KR20010075661A (en) * | 1998-10-23 | 2001-08-09 | 스티븐 엠. 오드레 | Methods and compositions for the prevention and treatment of anemia |
US7304150B1 (en) * | 1998-10-23 | 2007-12-04 | Amgen Inc. | Methods and compositions for the prevention and treatment of anemia |
AU2002233230B2 (en) | 2000-12-20 | 2007-02-01 | F. Hoffmann-La Roche Ag | Erythropoietin conjugates |
EP1909106B1 (en) * | 2001-09-14 | 2013-01-02 | F. Hoffmann-La Roche AG | Differential diagnosis of disorders of iron metabolism by means of four parameters and recommendations for the treatment of these disorders of iron metabolism |
US6930086B2 (en) | 2001-09-25 | 2005-08-16 | Hoffmann-La Roche Inc. | Diglycosylated erythropoietin |
US7300915B2 (en) * | 2002-06-05 | 2007-11-27 | The Regents Of The University Of California | Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain |
US7459435B2 (en) * | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
US7459436B2 (en) | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
US7964568B2 (en) * | 2003-05-30 | 2011-06-21 | Chromaceutical Advanced Technologies, Inc. | Synthesis of high molecular weight iron-saccharidic complexes |
US7772182B2 (en) * | 2004-08-05 | 2010-08-10 | Alza Corporation | Stable suspension formulations of erythropoietin receptor agonists |
US7586589B2 (en) * | 2005-09-24 | 2009-09-08 | Beckman Coulter, Inc. | Methods of determination of responsiveness to erythropoietin treatment |
CA2659990C (en) | 2006-08-04 | 2016-03-22 | Prolong Pharmaceuticals, Inc. | Polyethylene glycol erythropoietin conjugates |
CL2008002053A1 (en) * | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Method for the purification of a monopeglated erythropoietin (epompeg) which consists of providing a solution containing mono, poly and non-peglated erythropoietin and passing it through two steps of cation exchange chromatography and a method to produce epo mpeg that includes a purification method. |
AR067536A1 (en) * | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | METHOD FOR OBTAINING A MONO-PEGILATED ERYTHROPOYETIN IN A SUBSTANTIALLY HOMOGENOUS FORM |
BR112015031027A2 (en) * | 2013-06-13 | 2017-08-29 | Akebia Therapeutics Inc | USE OF A COMPOUND, IN VITRO METHOD, PHARMACEUTICAL COMPOSITION AND SINGLE DOSAGE FORM |
HUE052634T2 (en) | 2015-11-23 | 2021-05-28 | Bristol Myers Squibb Co | Additive systems for use in protein pegylation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6039681B2 (en) * | 1976-01-01 | 1985-09-07 | 日本臓器製薬株式会社 | Dextrin-citric acid-ferric polynuclear complex and parenteral iron preparation containing the complex |
IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
JPS6231A (en) * | 1985-02-06 | 1987-01-06 | Chugai Pharmaceut Co Ltd | Remedy for renal anemia |
US4745099A (en) * | 1985-02-06 | 1988-05-17 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of malignant tumors |
KR880012235A (en) * | 1987-04-10 | 1988-11-26 | 벤자민 에프.람버트 | How to increase hematocrit in normal mammals |
-
1995
- 1995-09-14 DE DE19535571A patent/DE19535571A1/en not_active Withdrawn
-
1996
- 1996-09-12 AT AT96932503T patent/ATE216256T1/en active
- 1996-09-12 KR KR10-1998-0701860A patent/KR100350761B1/en not_active IP Right Cessation
- 1996-09-12 DE DE19680768T patent/DE19680768D2/en not_active Expired - Lifetime
- 1996-09-12 IL IL12364096A patent/IL123640A0/en active IP Right Grant
- 1996-09-12 AU AU71282/96A patent/AU724623B2/en not_active Expired
- 1996-09-12 HU HU9900357A patent/HU225363B1/en unknown
- 1996-09-12 ES ES96932503T patent/ES2174107T3/en not_active Expired - Lifetime
- 1996-09-12 CA CA002231192A patent/CA2231192C/en not_active Expired - Lifetime
- 1996-09-12 PL PL96325640A patent/PL186776B1/en unknown
- 1996-09-12 TR TR1998/00472T patent/TR199800472T1/en unknown
- 1996-09-12 BR BR9609971-2A patent/BR9609971A/en not_active Application Discontinuation
- 1996-09-12 DK DK96932503T patent/DK0851762T3/en active
- 1996-09-12 CZ CZ1998726A patent/CZ291427B6/en not_active IP Right Cessation
- 1996-09-12 WO PCT/EP1996/003997 patent/WO1997009996A1/en active IP Right Grant
- 1996-09-12 EE EE9800066A patent/EE03856B1/en unknown
- 1996-09-12 DE DE59609099T patent/DE59609099D1/en not_active Expired - Lifetime
- 1996-09-12 MX MX9801922A patent/MX9801922A/en unknown
- 1996-09-12 EP EP96932503A patent/EP0851762B1/en not_active Expired - Lifetime
- 1996-09-12 JP JP51166197A patent/JP4783482B2/en not_active Expired - Lifetime
- 1996-09-12 NZ NZ319132A patent/NZ319132A/en not_active IP Right Cessation
- 1996-09-12 US US09/029,859 patent/US6333306B1/en not_active Expired - Lifetime
- 1996-09-12 CN CNB961982845A patent/CN1133463C/en not_active Expired - Lifetime
- 1996-09-12 PT PT96932503T patent/PT851762E/en unknown
- 1996-09-12 SK SK327-98A patent/SK285796B6/en not_active IP Right Cessation
- 1996-09-13 ZA ZA9607732A patent/ZA967732B/en unknown
- 1996-12-09 UA UA98041874A patent/UA57713C2/en unknown
-
1998
- 1998-03-11 IL IL123640A patent/IL123640A/en not_active IP Right Cessation
- 1998-03-13 NO NO19981136A patent/NO329908B1/en not_active IP Right Cessation
-
2001
- 2001-10-29 US US09/984,268 patent/US20020049161A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA967732B (en) | Pharmaceutical combination preparations containing erythropoietin and ferric complexes. | |
IL82209A0 (en) | Insulin preparation | |
HK1009239A1 (en) | Use of erythropoietin for the preparation of a pharmaceutical composition for pulmonary administration or inhalation | |
MX9707854A (en) | Pulmonary administration of dry powder alpha 1-antitrypsin. | |
CS653586A3 (en) | Pharmaceutical containing 7-isopropoxyisoflavone | |
HU911756D0 (en) | Process for the production of medical preparations containing magnesium-pyridoxal-5'-phosphate-glutaminate, for the preventing of arterial diseases | |
CA2284910A1 (en) | Pharmaceutical combined preparations containing erythropoietin and iron preparations | |
CA2060560A1 (en) | Method for insuring adequate intracellular glutathione in tissue | |
CA2127107A1 (en) | Methods and compositions for reducing blood loss | |
TWI263502B (en) | Pharmaceutical preparation for treating ischemic disease of heart or limbs | |
NZ514629A (en) | PEGylated interferon-alpha administered at about 4.5- 9.0 micrograms/kg/week as a renal cell carcinoma treatment | |
TR199902305T2 (en) | Pharmaceutical combination preparations containing erythropoitein and iron preparations. | |
GR3002381T3 (en) | Use of a carboxylic acid in pharmaceutical preparations intended for topical application | |
UA19647A (en) | Method for treatment of jaw osteomyelitis | |
UA10219A (en) | Method for treatment of pulmonary tuberculosis | |
HU9200147D0 (en) | Medical preparations with human interleukin-2 content | |
IL98276A0 (en) | Use of anaesthetic agents in the manufacture of pharmaceutical preparations for iontophoresis | |
BG94567A (en) | Medicaments for the treatment of aids and method for its application | |
CA2159609A1 (en) | Factor xiii for treatment of skin wounds | |
GB9017658D0 (en) | Inhaler for social and medical use |